证券代码：300149 证券简称：睿智医药 睿智医药科技股份有限公司投资者关系活动记录表 编号：2021-01 | --- | --- | --- | |----------------|--------------------|----------------------------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ | 现场参观 ■其他（机构交流活动） | | 参与单位名称及 | | 招商证券-许菲菲，中信证券-韩世通、王凯旋、陈竹，中泰证券-祝嘉琦、崔 | | 人员姓名 | | 少煜，浙商证券-王帅，英大资产-石晴川，兴业证券-黄翰漾，信达证券 - 王 | | | | | | | | 晓博、乔林建、陈怡晓、李慧瑶、孟阳，上海臻禾投资 - 穆其瑞，上海楹联 | | | | 健康产业投资-应振洲，青岛稳泰私募 - 刘晋宏，磐丰基金-孙凤强，盘京投 | | | 资 - | 曹 ...

编号：2021-02 证券代码：300149 证券简称：睿智医药 睿智医药科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-01 证券代码：300149 证券简称：睿智医药 睿智医药科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|----------------------------------|----------------------------------------------------------------------------| | | | | | 投资者关系活动 | □特定对象调研 | □分析师会议 | | 类别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | ■其他（线上投资者交流活动） | | 参与单位名称及 人员姓名 | 线上投资者 | | | 时间 | 2022 年 05 月 13 | 日下午 16:00-17:20 | | 地点 | "进门财经"电话会议 | | | 上市公司接待人 | 睿智医药董事长：曾宪维 | | | 员姓名 | 睿智医药 CEO | ：华风茂 | | | | | | | 睿智医药 CFO | ：夏丹樱 | | | 睿智医药 ...

编号：2022-03 证券代码：300149 证券简称：睿智医药 睿智医药科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | ■特定对象调研 | □分析师会议 | | 类别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 | □路演活动 | | | ■现场参观 | □其他 | | 参与单位名称及 | 德邦证券、君弘投资 公司 、东吴证券 | 、杉树资产 、方正证券 、中融基金 、光大证券 、中金 、沣青扬资产 、东海证券 、隐山资本 、德邦基金 、怀澄 | | 人员姓名 | 基金 、国金证券 | 、长江证券、瑞银资管 、时节创投 、富国基金 、中信证 ...

编号：2022-04 证券代码：300149 证券简称：睿智医药 睿智医药科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|--------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | □特定对象调研 | □分析师会议 | | 类别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | ■其他 | | 参与单位名称及 人员姓名 | 公司投资者 | | | 时间 | 2022 年 09 月 22 | 日下午 15:50-16:50 | | 地点 | 全景网"投资者关系 ...

3.第三季度报告是否经过审计 睿智医药科技股份有限公司 2022 年第三季度报告 证券代码：300149 证券简称：睿智医药 公告编号：2022-81 睿智医药科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）声明：保证季度报告中财务信 息的真实、准确、完整。 □是 否 1 睿智医药科技股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 期增减 | | 比上年同期增减 | | 营业收入（元） | 345,340,861.01 | -17.00% | ...

Financial Performance - The company's operating revenue for the reporting period was ¥686,896,517.51, a decrease of 18.75% compared to the same period last year [24]. - The net profit attributable to shareholders was ¥956,584,663.07, an increase of 18,518.34% year-on-year [24]. - The net cash flow from operating activities was ¥42,733,151.63, down 74.69% from the previous year [24]. - The total assets at the end of the reporting period were ¥4,827,190,365.64, reflecting a growth of 14.45% compared to the end of the previous year [24]. - The net assets attributable to shareholders increased by 49.04% to ¥2,927,779,378.95 [24]. - The company's revenue for the reporting period was approximately ¥686.90 million, a decrease of 18.75% compared to ¥845.39 million in the previous year, primarily due to the disposal of subsidiaries and the impact of the pandemic [70]. - The operating costs decreased by 25.16% to ¥449.95 million from ¥601.25 million, attributed to reduced revenue and the disposal of subsidiaries [70]. - The company's net profit for the first half of 2022 reached ¥956,537,485.31, a significant increase compared to ¥4,991,543.29 in the same period of 2021, representing a growth of approximately 19,100% [193]. - The total comprehensive income for the first half of 2022 was ¥968,350,619.69, compared to ¥3,082,337.59 in the first half of 2021, reflecting a significant increase [194]. Investment Activities - The company reported a significant increase in investment activities, with net cash flow from investment activities reaching ¥1.36 billion, a 998% increase compared to a net outflow of ¥151.77 million in the previous year [70]. - The company has established a pharmaceutical innovation investment fund with a total scale of 100 million USD, in which it contributed 30 million USD [153]. - The company has invested a total of 13,562,580.24 USD in the fund as of June 30, 2022 [153]. - The company acquired ChemPartner Corp. for ¥212,650,711.82 and Chemexplore Company Limited for ¥350,379,272.21, focusing on business expansion and research and development [78]. Operational Risks - The company reported a significant decline in service demand, which poses a risk to its operations [3]. - The company is facing risks related to core technology and management personnel loss, as well as potential failures in new technology development [3]. - The management emphasizes the importance of risk awareness among investors regarding future plans and performance forecasts [3]. - The company has outlined various operational risks and corresponding countermeasures in the management discussion section [3]. - The company faces risks related to the loss of key scientific and management personnel, which could significantly impact its operations and service quality [100]. - There is a risk of failure in new technology development, which is critical for maintaining competitiveness; the company plans to invest in personnel and capital for innovation [101]. Compliance and Regulatory Matters - The company must comply with various legal and regulatory requirements to obtain necessary licenses and approvals for its operations, with non-compliance potentially leading to severe penalties [106]. - The company is committed to enhancing its quality management systems to meet regulatory requirements and mitigate risks associated with government oversight [103]. - The company has established hazardous waste storage facilities with protective measures to collect and dispose of hazardous waste in compliance with regulations [122]. - The company has actively revised its environmental emergency response plans in compliance with local regulations and has filed these plans with relevant environmental authorities [124]. Shareholder Matters - No cash dividends, bonus shares, or capital reserve transfers will be distributed to shareholders [4]. - The company does not plan to distribute cash dividends or issue bonus shares for the half-year period [116]. - The company granted 25.71 million shares of restricted stock to 116 incentive recipients at a price of 7.16 CNY per share on September 29, 2021 [118]. - Due to the departure of 34 incentive recipients and unmet performance assessment requirements, 11.577 million shares of restricted stock were canceled, reducing the total to 14.133 million shares for 82 recipients [118]. Market Position and Strategy - The company is positioned in the pharmaceutical R&D and production service industry, benefiting from global trends such as population growth and increased healthcare awareness [33]. - The company has established a strong market position with approximately 3,000 global clients, providing integrated solutions from early drug discovery to large-scale production [36]. - The company has established a strong presence in the pharmaceutical industry through strategic partnerships and collaborations [15]. - The company operates as an integrated platform focused on pharmaceutical research and development services, with its success closely tied to the number and value of service agreements with clients [99]. Environmental Responsibility - The company has implemented an environmental self-monitoring plan, including annual monitoring of waste gas and quarterly monitoring of wastewater and noise, to enhance monitoring accuracy [125]. - During the reporting period, Ruizhi Pharmaceutical Jiangsu Co., Ltd. faced an administrative penalty of CNY 9,600 for failing to conduct self-monitoring as per the pollution discharge permit [126]. - The company emphasizes its commitment to social responsibility, focusing on compliance, product quality, employee development, and environmental protection, aiming for a balance between economic and social benefits [129]. Financial Structure and Assets - The company has a total of ¥55,269,617.53 in restricted assets, including cash, fixed assets, and intangible assets, primarily due to bank loan collateral [81]. - The company’s inventory decreased to ¥44,492,655.49, representing 0.92% of total assets, down from 1.63% last year [76]. - The company’s fixed assets decreased to ¥502,857,961.12, accounting for 10.42% of total assets, down from 15.91% last year, mainly due to the disposal of subsidiaries [76]. - The company reported a total investment of ¥14,535,319.49 during the reporting period, a decrease of 17.00% compared to ¥17,412,982.60 in the same period last year [83].

睿智医药科技股份有限公司 2022 年第一季度报告全文 证券代码：300149 证券简称：睿智医药 公告编号：2022-43 睿智医药科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中 财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 386,301,922.70 | 389,706,314.16 | -0.87% | | 归属于上市公司股东的净利润（元） | 9,470,996.67 | 1,631,770 ...

Financial Performance - The company reported a significant loss primarily due to a large goodwill impairment and an increase in period expenses [4]. - The company's total revenue for 2021 was ¥1,690,677,943.33, representing a 14.11% increase from ¥1,481,591,872.64 in 2020 [20]. - The net profit attributable to shareholders was -¥402,245,074.78, a decrease of 360.27% compared to a profit of ¥154,550,403.78 in 2020 [20]. - The net cash flow from operating activities was ¥378,219,891.25, up 10.22% from ¥343,160,357.56 in the previous year [20]. - The total assets at the end of 2021 amounted to ¥4,217,591,526.68, a 2.33% increase from ¥4,121,581,017.24 at the end of 2020 [20]. - The net assets attributable to shareholders decreased by 19.09% to ¥1,964,444,590.44 from ¥2,427,903,737.42 in 2020 [20]. - The basic earnings per share for 2021 was -¥0.81, a decline of 361.29% from ¥0.31 in 2020 [20]. - The weighted average return on equity was -18.40%, down 24.95% from 6.55% in 2020 [20]. - In Q4 2021, the company reported a net profit attributable to shareholders of -¥417,078,237.49, significantly impacting the annual results [22]. - The company reported a total revenue after deductions of ¥1,684,522,730.56 for 2021 [20]. Business Strategy and Focus - The company plans to focus on its core business to enhance its industry position and sustainable development capabilities [4]. - The company plans to divest its prebiotic business to focus on CRO/CDMO services, with the sale of Quantum High-Tech (Guangdong) Bio Co., Ltd. approved by shareholders [32]. - The company aims to expand its domestic market presence, optimizing its customer operation system to increase market share in China's rapidly growing pharmaceutical market [105]. - The company is advancing the construction of a 4500L capacity production base in Qidong, Jiangsu, to enhance its biopharmaceutical production capabilities [106]. - The company is actively pursuing market expansion strategies, including potential mergers and acquisitions to strengthen its market position [143]. Risks and Challenges - The company faces various risks, including a decline in service demand and potential failure in new technology development [5]. - Future plans and performance forecasts do not constitute commitments to investors, highlighting the need for risk awareness [5]. - The company faces risks related to declining demand for pharmaceutical R&D services, which could significantly impact its business if industry growth slows [109]. - The company acknowledges the risk of goodwill impairment from its acquisition of Shanghai Ruizhi, emphasizing the need for effective resource integration to mitigate this risk [115]. - The company faces risks related to obtaining necessary qualifications for drug research and production, which could lead to sanctions or operational interruptions if not secured [117]. Governance and Management - The audit report issued by Ernst & Young included a paragraph on significant uncertainties regarding the company's ability to continue as a going concern [4]. - The company’s financial report has been confirmed as true, accurate, and complete by its management team [3]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with governance standards and effective decision-making [127]. - The company has established a performance evaluation and incentive mechanism to align executive compensation with company performance, promoting long-term stability [131]. - The company has implemented measures to ensure transparency and equal access to information for all shareholders [132]. Research and Development - The company has developed a database of 8 million small molecules for virtual screening, enhancing its drug design capabilities [36]. - The company has submitted a patent application for a new GalNAc drug delivery molecule, expanding its capabilities in peptide chemistry [36]. - The company has developed a series of advanced technology platforms for drug discovery, including CRISPR target validation and gene-encoded compound libraries [60]. - The company’s R&D expenses reached CNY 124,652,569.11, a 73.91% increase compared to the previous year, driven by investments in technology platform innovation [78]. Environmental Responsibility - The company has established a comprehensive environmental protection management system, with specific departments responsible for executing environmental protection tasks [195]. - The company actively promotes green chemistry initiatives, focusing on reducing the environmental impact of chemical use from the source [196]. - The company conducts annual soil and groundwater testing, with reports submitted to the local ecological environment bureau [193]. - The company has installed online monitoring systems for wastewater and air emissions, ensuring real-time data transmission to the Shanghai Environmental Protection Bureau [192]. - The company has made significant investments in environmental protection, resulting in improved management and technical levels [194]. Shareholder Relations - No cash dividends or stock bonuses will be distributed to shareholders [6]. - The company reported a total cash dividend amount of ¥20,443,281.30 from share repurchases, with no cash dividends or stock bonuses distributed to shareholders for the fiscal year 2021 [169]. - The company incurred losses for the fiscal year 2021 and decided not to distribute profits to ensure sufficient funding for long-term development [170]. - The company has a clear strategy for maintaining operational independence from its controlling shareholders [135].

Financial Performance - The company's revenue for Q3 2021 was ¥416,090,491.65, representing a 4.25% increase compared to the same period last year[4] - The net profit attributable to shareholders decreased by 77.14% to ¥9,695,301.07, while the net profit excluding non-recurring gains and losses dropped by 89.20% to ¥3,916,277.66[4] - In the first three quarters of 2021, the company achieved a total revenue of RMB 1,261.48 million, representing a year-on-year growth of 17.97%[20] - The net profit attributable to shareholders for the first three quarters of 2021 was RMB 14.83 million, a decline of 82.19% year-on-year[21] - In Q3 2021, the net profit attributable to shareholders was RMB 9.70 million, down 77.14% year-on-year, primarily due to increased labor costs and initial costs from the commercial production project in Qidong, Jiangsu[21] - The total comprehensive income for Q3 2021 was CNY 14,024,461, compared to CNY 73,509,840 in Q3 2020, reflecting a decline of 81.0%[31] - The basic and diluted earnings per share for Q3 2021 were both CNY 0.03, down from CNY 0.17 in Q3 2020[31] Assets and Liabilities - Total assets increased by 16.94% to ¥4,819,831,851.24 compared to the end of the previous year[4] - Total liabilities rose to ¥2,408,610,396.23 from ¥1,669,193,302.07, marking an increase of about 44%[27] - Total assets amounted to approximately ¥4.12 billion, with a significant increase to ¥4.71 billion after adjustments[38] - Current assets totaled approximately ¥919.88 million, while non-current assets reached approximately ¥3.20 billion[38] - Total liabilities were approximately ¥1.67 billion, with non-current liabilities accounting for about ¥881.59 million[38] Cash Flow - The cash flow from financing activities decreased by 65.68% to ¥47,288,299.37, primarily due to reduced net borrowings and dividend payments during the reporting period[12] - Cash flow from operating activities generated a net amount of CNY 262,135,150.87, an increase of 24.7% from CNY 210,247,510.40 in the previous year[34] - Cash and cash equivalents as of September 30, 2021, were ¥318,619,661.89, compared to ¥259,121,396.09 at the end of 2020, indicating a growth of about 23%[25] - Cash and cash equivalents at the end of Q3 2021 totaled CNY 305,332,809.78, up from CNY 236,978,183.67 at the end of Q3 2020[34] - Investment activities resulted in a net cash outflow of CNY 249,156,566.84, an improvement from a net outflow of CNY 308,190,992.18 in the same period last year[34] Research and Development - Research and development expenses surged by 99.53% to ¥90,982,840.49, indicating increased investment in pharmaceutical R&D and production outsourcing services[11] - Research and development expenses increased significantly to CNY 90,982,840, up 99.5% from CNY 45,599,044 in the same period last year[30] Shareholder Information - The company’s total equity attributable to shareholders decreased by 1.69% to ¥2,386,874,098.93 compared to the end of the previous year[4] - The company’s equity attributable to shareholders decreased from ¥2,427,903,737.42 to ¥2,386,874,098.93, a decline of about 2%[27] - The company’s major shareholder, Yunnan Baben Health Industry Co., Ltd., holds 15.28% of the shares, with 76,342,300 shares pledged[16] - The top ten shareholders collectively hold significant stakes, with the largest shareholder having 15.28% of the total shares[16] Operational Performance - Total operating revenue for the period reached ¥1,261,483,497.11, an increase of approximately 18% compared to ¥1,069,362,339.50 in the previous period[29] - Total operating costs amounted to ¥1,261,078,461.21, up from ¥985,350,121.86, reflecting a significant rise in operational expenses[29] - The company reported a significant increase in sales revenue, with cash received from sales reaching CNY 1,315,426,854.98, compared to CNY 1,065,140,303.11 in the previous year, marking a growth of 23.5%[32] Inventory and Receivables - Accounts receivable decreased to ¥360,671,069.79 from ¥384,470,762.02, showing a reduction of approximately 6%[25] - The company reported a decrease in inventory from ¥54,807,328.19 to ¥64,320,928.92, indicating a change in inventory management strategy[25] - Inventory was valued at approximately ¥54.81 million, suggesting effective inventory control[37] Management and Future Outlook - The company plans to enhance its compensation incentive system to address rising labor costs[21] - The micro-ecological health business is expected to continue growing due to increased market share and customer base[21] - The company experienced a significant increase in management expenses, which rose to CNY 193,356,100.55, compared to CNY 166,708,677.26 in the previous year, reflecting a rise of 15.9%[30] Compliance and Audit - The company has not yet audited the third-quarter report, which may affect the reliability of the financial data presented[40] - The company is in compliance with the new leasing standards, which may impact future financial reporting[40]